Feline nasal granuloma due to Cryptoccocus gattii type VGII.
The aims of this study are to make a more precise identification of the etiologic agent of a nasal granuloma in a cat, to verify the susceptibility to the antifungal drugs: ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole, amphotericin B and the proper treatment. Part of the granuloma's fragment was removed, added to a saline solution and sent to the Laboratory of Mycology. The solution was then seeded in Sabouraud dextrose agar, and the yeast was primarily identified by the traditional methods. The confirmation of the specie Cryptococcus gattii and its molecular type were performed using the PCR-RFLP molecular techniques. The antifungal susceptibility was verified by using the E-test method, and the cat was treated with itraconazole associated with 5-flucytosine. The isolated strain was identified as C. gattii type VGII and was susceptible to all antifungal drugs tested. The treatment with itraconazole associated with 5-flucytosine led to the cure of granulomatous lesions in the feline after 6 months. The characterization and molecular investigation of this microorganism are relevant because they could help us better understand the epidemiology of the infection and to guide us to treat properly the disease.
Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, USP, São Paulo, Brazil.
Pedro Henrique Magalhães
PH
Cardoso
Francisco de Assis
Fde A
Baroni
Eriques Gonçalves
EG
Silva
Diana Costa
DC
Nascimento
Marilena Dos Anjos
Mdos A
Martins
Walderez
W
Szezs
Claudete Rodrigues
CR
Paula
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D002371:Cat Diseases / Q000175:diagnosis* / Q000382:microbiology* / Q000473:pathology; D002415:Cats; D003453:Cryptococcosis / Q000175:diagnosis / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D056285:Cryptococcus gattii / Q000302:isolation & purification*; D005437:Flucytosine / Q000627:therapeutic use; D006099:Granuloma / Q000209:etiology* / Q000473:pathology*; D017964:Itraconazole / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D008828:Microbiological Techniques; D025202:Molecular Diagnostic Techniques; D009668:Nose Diseases / Q000175:diagnosis / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D016896:Treatment Outcome
D000935:Antifungal Agents; D017964:Itraconazole; D005437:Flucytosine